Robert Wills, Ph.D., currently serves as the Executive Chairman of GTx, Inc, Chairman of the Board of CymaBay Therapeutics, Board member at Parion Sciences, Inc, and a member of the Emerging Companies Section Governing Board of BIO. Prior to these roles, Dr. Wills spent over 25 years at Johnson & Johnson and 10 years at Hoffmann-LaRoche. He holds a BS in Biochemistry, MS in Pharmaceutics from the University of Wisconsin and a PhD in Pharmaceutics from the University of Texas.